193150-92-4

Upstream product

• 4348-68-9 2,3,5-tri-O-benzoyl-α-D-arabinofuranosyl bromide 
• 56607-40-0 methyl D-arabinofuranoside 
• 193150-87-7 1-(2-benzoyl-α-D-arabinofuranosyl)-2-nitroimidazole 
• 7473-42-9 methyl tri-O-benzoyl-α-D-arabinofuranoside 
• 83416-39-1 1-(2,3,5-tri-O-benzoyl-α-D-arabinofuranosyl)-2-nitroimidazole 
• 28697-53-2 D-arabinopyranose 
• 83416-40-4 1-α-D-(arabinofuranosyl)-2-nitroimidazole 

Downstream Products

• 1352939-30-0 1-α-D-(5'-O-(4-nitrobenzenesulfonyI)-2',3'-di-O-pivaloyl-arabinofuranosyl)-2-nitroimidazole 
• 1352939-20-8 1-α-D-(5'-O-(4-nitrobenzenesulfonyI)-2',3'-di-O-acetyl-arabinofuranosyl)-2-nitroimidazole 
• 138172-12-0 1-(5-deoxy-5-[125]iodo-α-D-arabinofuranosyl)-2-nitroimidazole 

Relevant academic research and scientific papers

The synthesis and radiolabeling of novel markers of tissue hypoxia of the iodinated azomycin nucleoside class

Seven second-generation hypoxic markers of the iodinated azomycin nucleoside class have been synthesized and tested for hypoxia marking activity with tumor cells in vitro and in vivo. β-D-lodoazomycin galactoside (IAZG) and β-D-lodoazomycin xylopyranoside (IAZXP) demonstrated superior hypoxia marking properties relative to IAZA because of their higher water solubilities, rapid plasma clearance rates from tumor-bearing mice and maximum tumor/blood (T/B) and tumor/muscle (T/M) ratios. Our studies with animal tumor models show that T/B or T/M ratios of these markers determined by scintigraphy or planar imaging can predict for the relative degree of tumor hypoxia and for tumor radioresistance.

COMPOUNDS USEFUL IN IMAGING AND THERAPY

As described herein there is provided novel precursors/synthons, and their chemical and radiochemical derivatives and methods of use thereof.